Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
P/S ratio for Mirati Therapeutics, Inc. (MRTX)
P/S ratio as of 2022: 204.88
According to Mirati Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 204.88. At the end of 2021 the company had a P/S ratio of 105.57.
P/S ratio history for Mirati Therapeutics, Inc. from 2003 to 2022
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2022 | 204.88 |
| 2021 | 105.57 |
| 2020 | 737.50 |
| 2019 | 1447.70 |
| 2018 | 101.40 |
| 2017 | 0.00 |
| 2016 | 0.00 |
| 2015 | 0.00 |
| 2014 | 0.00 |
| 2013 | 0.00 |
| 2012 | 34919.56 |
| 2011 | 14.80 |
| 2010 | 2.39 |
| 2009 | 1.83 |
| 2008 | 0.21 |
| 2007 | 0.32 |
| 2006 | 0.29 |
| 2005 | 0.53 |
| 2004 | 0.35 |
| 2003 | 0.30 |